Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1980 1
1981 1
1983 1
1984 1
1985 1
1986 1
1995 2
1996 1
1997 2
1998 5
1999 2
2000 6
2001 1
2002 9
2003 11
2004 10
2005 25
2006 16
2007 21
2008 23
2009 20
2010 24
2011 28
2012 39
2013 48
2014 29
2015 32
2016 46
2017 42
2018 61
2019 56
2020 81
2021 80
2022 58
Text availability
Article attribute
Article type
Publication date

Search Results

700 results
Results by year
Filters applied: . Clear all
Page 1
Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19.
Zhao J, Tian S, Lu D, Yang J, Zeng H, Zhang F, Tu D, Ge G, Zheng Y, Shi T, Xu X, Zhao S, Yang Y, Zhang W. Zhao J, et al. Among authors: tu d. Phytomedicine. 2021 May;85:153315. doi: 10.1016/j.phymed.2020.153315. Epub 2020 Sep 9. Phytomedicine. 2021. PMID: 32978039 Free PMC article.
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, Colwell B, Samimi S, Samson B, Abbas T, Aucoin N, Aubin F, Koski SL, Wei AC, Magoski NM, Tu D, O'Callaghan CJ. Chen EX, et al. Among authors: tu d. JAMA Oncol. 2020 Jun 1;6(6):831-838. doi: 10.1001/jamaoncol.2020.0910. JAMA Oncol. 2020. PMID: 32379280 Free PMC article. Clinical Trial.
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Goss PE, et al. Among authors: tu d. N Engl J Med. 2016 Jul 21;375(3):209-19. doi: 10.1056/NEJMoa1604700. Epub 2016 Jun 5. N Engl J Med. 2016. PMID: 27264120 Free PMC article. Clinical Trial.
The prognostic effects of somatic mutations in ER-positive breast cancer.
Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, Hundal J, Ainscough BJ, Skidmore ZL, Campbell K, Kumar R, Fronick C, Cook L, Snider JE, Davies S, Kavuri SM, Chang EC, Magrini V, Larson DE, Fulton RS, Liu S, Leung S, Voduc D, Bose R, Dowsett M, Wilson RK, Nielsen TO, Mardis ER, Ellis MJ. Griffith OL, et al. Among authors: tu d. Nat Commun. 2018 Sep 4;9(1):3476. doi: 10.1038/s41467-018-05914-x. Nat Commun. 2018. PMID: 30181556 Free PMC article.
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Shi T, et al. Among authors: tu d. Lancet Oncol. 2021 Apr;22(4):439-449. doi: 10.1016/S1470-2045(21)00006-1. Epub 2021 Mar 8. Lancet Oncol. 2021. PMID: 33705695 Clinical Trial.
Isomeric anthracene diimide polymers.
Tu D, Yang Q, Yu S, Guo X, Li C. Tu D, et al. Chem Sci. 2021 Jan 13;12(8):2848-2852. doi: 10.1039/d0sc06164f. Chem Sci. 2021. PMID: 34164049 Free PMC article.
700 results